Sionna: A Biotech Bounce & My Portfolio Anxiety

by

Right. So, another day, another stock doing… things. This time it’s Sionna Therapeutics (SION 2.34%). Honestly, my portfolio is starting to feel like a particularly chaotic dating life – a lot of potential, a lot of disappointment, and a constant fear of being blindsided. Apparently, Superstring Capital Management has taken a shine to them, buying up 180,593 shares in the last quarter. A significant amount of money, really. $7.43 million, to be precise. Which, let’s be honest, is more than I’ve made in several months. Possibly years. Don’t dwell on that.

What Happened (and Why I’m Overthinking It)

February 17th, 2026, saw Superstring making their move. It’s 3.98% of their 13F reportable AUM, which sounds impressive, but honestly, percentages always make things sound more substantial than they are. Like a tiny portion of chocolate cake appearing much larger on a small plate. Their top holdings, for context (because context is everything, isn’t it?) are:

  • NASDAQ:CDTX: $18.80 million (10.1% of AUM)
  • NASDAQ:TERN: $17.93 million (9.6% of AUM)
  • NASDAQ:URGN: $16.82 million (9.0% of AUM)
  • NASDAQ:COGT: $13.01 million (7.0% of AUM)
  • NASDAQ:DVAX: $8.08 million (4.3% of AUM)

And Sionna, nestled in there somewhere. It’s all a bit… precarious, isn’t it? The stock itself has had a bit of a moment, up 144% over the past year. Which is… good? I think? It certainly outperforms the S&P 500’s rather pedestrian 19% gain. One has to ask oneself, is this sustainable? Is it a bubble? Is it a sign that I should be aggressively buying, or frantically selling? The questions never end.

The Numbers (Because One Must Be Rational)

Here’s a little table, for those who like things laid out. I’m more of a “vague sense of unease” kind of investor, but one must attempt objectivity:

Metric Value
Price (as of Wednesday) $34.99
Market capitalization $1.6 billion
Net income (TTM) ($75.3 million)

What Sionna Actually Does (Beyond Making My Portfolio Nervous)

Okay, so they develop biopharmaceutical therapies for cystic fibrosis. Specifically, they’re trying to restore the function of something called the cystic fibrosis transmembrane conductance regulator (CFTR). It sounds complicated. And probably is. Basically, they’re targeting a rare disease, which is… a strategy. It’s either incredibly noble or incredibly risky. Possibly both. They’re based in Waltham, Massachusetts, which, frankly, feels a long way away from my sofa.

Sionna is a clinical-stage company, which means they’re still testing things. Still hoping things will work. Like me, on a Monday morning. They’re focused on CFTR modulators, which is a fancy way of saying they’re trying to fix the underlying cause of the disease. It’s a competitive landscape, apparently. Everything is competitive. Even breathing, sometimes.

So, What Does This Mean for Me? (and My Increasingly Frazzled Nerves)

Right. The important bit. Sionna is at a crucial point. Phase 1 and Phase 2 data are expected mid-year. That’s when things could really move. Or really crash. It’s the nature of biotech, I suppose. A bit like dating, really – a lot of potential, a lot of disappointment, and a constant fear of being blindsided.

They’ve had a good year, admittedly. The stock’s surged, Phase 1 trials were positive. And they’ve got around $310 million in cash. Which, in biotech terms, is a decent amount. It gives them runway into 2028, even as their spending climbs. Which is good. Because running out of cash is never good. It’s like realizing you’ve eaten all the biscuits. A moment of profound regret.

Units of Cryptocurrency Lost: 2. Hours Spent Watching Charts: 7. Number of Panicked Texts to Friends: 18. I think I need a biscuit.

Read More

2026-03-18 18:34